An experimental oral therapy called SHetA2 could help stop persistent HPV infections from progressing to cervical cancer by targeting the virus's cancer-causing proteins. While early studies are promising, larger human clinical trials are still needed. Experts stress that HPV vaccination and regular cervical screening remain essential for preventing cervical cancer.